LEXXW - Lexaria Awarded New Patents
(TheNewswire)
Lexariareceives new patents in the fields of epilepsy and anti-viralagents
Kelowna, British Columbia – April2, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX;LEXXW) (the “Company” or “Lexaria”), a global innovator indrug delivery platforms announces three recentpatent awards.
The Company has recently received two new grantedpatents in Lexaria’s patent family #24, Compositions and Methods for TreatingEpilepsy , both awarded in the USA. These patents complement earlierresearch that discoveredDehydraTECH-CBD was capable of mitigating epileptic seizures inrodents, and was also absorbed into the bloodstream more effectivelythan the commercially available cannabinoid-based anti-seizuremedication, Epidiolex®. Each of these patents will expire in 2042 ifnot extended. These are the first patents awarded to Lexaria withinthis important patent family, where there are also internationalapplications currently being processed, and they cover both swallowedcapsules and dissolvable oral tablets.
The Company has received a granted patent in Japan inLexaria’s patent family #18: Compositions and Methods for Enhanced Delivery of AntiviralAgents. Lexaria previously established in animalstudies, that DehydraTECH processing of several antiviral drugsresulted in delivery improvements ofbetween 42% and 204% . This newlyissued patent will expire in 2041, if not extended. The new Japanesepatent follows previous patent grants within this patent family inAustralia and the USA.
With the issuance of these new patents, Lexaria is nowmanaging a patent portfolio of 41 granted patents worldwide.Lexaria’s intellectual property remains a significant component insupporting future business objectives.
About Lexaria Bioscience Corp. &DehydraTECH
DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the wayactive pharmaceutical ingredients (APIs) enter the bloodstream throughoral delivery. Since 2016, Lexaria has developed and investigatedDehydraTECH with a variety of beneficial molecules in oral and topicalformats. DehydraTECH has repeatedly demonstrated the ability toincrease bio-absorption and has also evidenced an ability to deliversome drugs more effectively across the blood brain barrier, whichLexaria believes to be of particular importance for centrally activecompounds. Lexaria operates a licensed in-house research laboratoryand holds a robust intellectual property portfolio with 41 patentsgranted and many patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatory approvals or grants or experience positiveeffects or results from any research or study. Such forward-lookingstatements are estimates reflecting the Company's best judgment basedupon current information and involve a number of risks anduncertainties, and there can be no assurance that the Company willactually achieve the plans, intentions, or expectations disclosed inthese forward-looking statements. As such, you should not placeundue reliance on these forward-looking statements. Factors whichcould cause actual results to differ materially from those estimatedby the Company include, but are not limited to, government regulationand regulatory approvals, managing and maintaining growth, the effectof adverse publicity, litigation, competition, scientific discovery,the patent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. TheCompany provides links to third-party websites only as a courtesy toreaders and disclaims any responsibility for the thoroughness,accuracy or timeliness of information at third-party websites. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements or links to third-party websites contained herein, whetheras a result of any new information, future events, changedcircumstances or otherwise, except as otherwise required bylaw.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2024 TheNewswire - All rights reserved.